Jeff Yass’s Avalo Therapeutics AVTX Stock Holding History

Jeff Yass’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.47M	Sell	241,900 -232,300	-49%	-$3.67M	﹤0.01%	4847
2026 Q1	$7.08M	Buy	474,200 +413,500	+681%	+$6.47M	﹤0.01%	3639
2025 Q4	$1.1M	Buy	60,700 +10,000	+20%	+$169K	﹤0.01%	6958
2025 Q3	$644K	Buy	+50,700	New	+$436K	﹤0.01%	8394
2022 Q1	–	Sell	-25	Closed	-$122K	–	12950
2021 Q4	$122K	Sell	25 -4	-14%	-$24K	﹤0.01%	11992
2021 Q3	$182K	Buy	29 +10	+53%	+$81.1K	﹤0.01%	11601
2021 Q2	$182K	Buy	19 +13	+217%	+$109K	﹤0.01%	11687
2021 Q1	$50K	Buy	+6	New	+$56.7K	﹤0.01%	12032
2018 Q4	–	Sell	-5	Closed	-$62K	–	8906
2018 Q3	$62K	Buy	+5	New	+$65.5K	﹤0.01%	8778

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jeff Yass's AVTX Position: Q2 2026 in Review

Jeff Yass opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 27,227 shares worth $503K. The stake represents ﹤0.01% of the portfolio and ranks #9914 among its holdings. This is a return to the name: Jeff Yass previously reported a position in AVTX as recently as Q4 2025.

Jeff Yass first reported a position in AVTX in Q1 2019 and has held it in 16 quarters since. The position peaked at $3.83M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Jeff Yass held 27,227 shares of Avalo Therapeutics worth $503K as of Q2 2026.
Avalo Therapeutics was a new Jeff Yass position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9914 holding.
Jeff Yass first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 16 quarters since.
Jeff Yass's Avalo Therapeutics position peaked at $3.83M in Q4 2025.
125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.